The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Role of Hepatitis B Surface Antibodies in Risk for Hepatitis B Virus Reactivation During Anti-Tumor Necrosis Factor Therapy
Clin Gastroenterol Hepatol. 2022 Feb 18;S1542-3565(22)00183-5.doi: 10.1016/j.cgh.2022.02.027. Online ahead of print.
1Division of Gastroenterology Hepatology & Nutrition, Department of Medicine, East Carolina University/Vidant Medical Center, Greenville, North Carolina.
2Department of Internal Medicine, East Carolina University/Vidant Medical Center, Greenville, North Carolina.
3Vidant Medical Center, Greenville, North Carolina.
4Research Librarian for the Health Sciences, East Carolina University, Greenville, North Carolina.
5Division of Gastroenterology, Hepatology & Nutrition, Department of Medicine, East Carolina University/Vidant Medical Center, Greenville, North Carolina. Electronic address: Tillmannh14@ecu.edu.
Abstract
An estimated 250 million people are chronically infected with hepatitis B virus (HBV), with more than 800,000 deaths related to HBV.1 Although the prevalence of HBV has been decreasing, reactivation remains a cause for concern.2 Reactivation is defined by the resurgence of HBV DNA and/or HBV surface antigen (HBsAg) seroreversion in patients with resolved HBV or an increase in HBV viral load in chronic hepatitis.3 Anti-tumor necrosis factor (TNF) therapies have been shown to place patients at a risk for HBV reactivation.4.